Welcome to our dedicated page for Bioquest news (Ticker: BQST), a resource for investors and traders seeking the latest updates and insights on Bioquest stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bioquest's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bioquest's position in the market.
BioQuest (OTC PINK:BQST) has appointed Ed Preble as Chief Technology Officer (CTO), following its recent acquisition of BotMakers, a conversational AI platform. This appointment marks BioQuest's strategic shift from biotechnology to AI automation technology.
Preble brings over 40 years of experience in technology innovation and business growth, with expertise in AI, SaaS, telecom automation, and enterprise infrastructure. He previously served as CEO of Affinity VoIP Telecom and was a professor of eCommerce at San Jose State University.
Following the BotMakers acquisition, BioQuest is expanding its AI-powered solutions including:
- Conversational AI agents for lead engagement
- Omnichannel social media automation
- AI-generated funnels and CRM automations
- Biotech-specific AI solutions for clinical communication
BioQuest (OTC PINK:BQST) has completed its acquisition of BotMakers, a leader in AI-powered conversational technology, and appointed Trent T. Daniel as CEO. The company, trading above $1 per share, previously secured SEC clearance for a $5 million Regulation A offering to fund marketing and platform development.
BotMakers expects to generate revenues exceeding $1.2 million this year, targeting $5 million by end-2026. The company serves notable clients including Infinity Concepts and Colonial Stock Transfer. BotMakers secured a contract with 3Mark Financial for implementing conversational AI technology.
BioQuest plans to rebrand as BotMakers and is negotiating to acquire an AI-powered marketing leads company generating over $1 million in annual revenue. The acquisition strengthens BioQuest's position in enterprise-level AI solutions and automated digital workforce solutions for government, corporate, and law enforcement sectors.
FAQ
What is the current stock price of Bioquest (BQST)?
What is the market cap of Bioquest (BQST)?
